Oprelvekin

Thrombopoietic factors (no recombinant TPO product in clinical use at this time IL-11 [recombinant product oprelvekin] has marketing approval) stimulate the production of megakaryocyte precursors, megakaryocytes, and platelets [8]. Interleukin-11 has many effects on multiple tissues, and can interact with IL-3, TPO, and SCF. AMG 531, a recombinant peptibody in that binds to the thrombopoetin receptor Mpl and stimulates the production of platelets, is in phase 1 and 2 studies and has been shown to safely increase platelet counts in patients with immune thrombocytopenic purpura [9]. 

Neumega Oprelvekin Genetics Institute Prevention of severe chemotherapy-induced thrombocytopenia... 

Oprelvekin -stimulation of megakaryoctye proliferation (IL-11, -fluid retention... 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

In the reported error, a physieian used the abbreviation IL-ll when ordering oprelvekin for a patient. Unfortimately, the order was misinterpreted to be interleukin-2 (i.e., the number eleven was pereeived to be the Roman numeral two). Five or more health eare professionals, ineluding pharmacists and nurses, mistook the order to be aldesleukin. The error was not detected for four days, until it was noted that the inventory of aldesleukin was nearly depleted. 

Filgrastim [G-CSF] (Neupogen) Oprelvekin (Neumega) Pegfilgrastim (Neulasta)... 

Platelets, small cell fragments produced from bone marrow cells, work with the cascade of proteins in the formation of blood clots. If platelet counts are low, leaks in blood vessels that would normally be small can lead to the loss of large amoimts of blood. Certain chemotherapy drugs knock out the production of the cells that produce platelets. Oprelvekin (Neumega ), produced in E. coli, stimulates bone marrow to produce that very important type of cell. 

Dosage form Neumega is available for injection in single-use vials containing 5 mg of oprelvekin as a sterile lyophilized powder. It is reconstituted by the addition of sterile water for injection. 

Metabolism One report suggests that oprelvekin is extensively metabolized in the kidneys. 

G. Other considerations Recombinant human oprelvekin has been designated an orphan product for use in the prevention of chemotherapy-induced thrombocytopenia. 

Oprelvekin, human recombinant IL-11, a thrombopoietic growth factor that stimulate stem cells and megakaryocyte progenitor, produced in E. coli... 

Interleukin-11 (IL-11, oprelvekin) Thrombocytopenia Patients with nonmyeloid malignancies who receive myelosuppressive cancer chemotherapy... 

Interleukin-11 is a 65-85 kDa protein produced by fibroblasts and stromal cells in the bone marrow. Oprelvekin, the recombinant form of IL-11 approved for clinical use (Table 33-4), is produced by expression in Escherichia coli. The half-life of IL-11 is 7-8 hours when the drug is injected subcutaneously. 

Oprelvekin Recombinant Stimulates the Secondary prevention of Administered daily by SC injection ... 

Parenteral (Iron dextran) (InFeD, DexFerrum) 50 mg elemental iron/mL Parenteral (Sodium ferric gluconate complex) (Ferrlecit) 12.5 mg elemental iron/mL Parenteral (Iron sucrose) (Venofer) 20 mg elemental iron/mL Oprelvekin (IL-11) (Neumega)... 

NEUMEGA (Oprelvekin) Wyeth-Ayerst [E. coli expressed recombinant thrombotic growth factor]... 

Recombinant human IL-11 (oprelvekin) is a polypeptide of 177 amino acids. It differs from natural IL-11 due to lack of glycosylation and the amino-terminal proline residue. Oprelvekin is administered by subcutaneous injection, usually 6-24 h after chemotherapy, at a dose of 25-50 p,g/kg per day. The drug has a half-life of about 7h. It is used to stimulate bone marrow to induce platelet production in nonmyeloid malignancies in patients undergoing chemotherapy. The common side effects of oprelvekin include fluid retention, tachycardia, edema, nausea, vomiting, diarrhea, shortness of breath and mouth sores. Other side effects include rash at the injection site, blurred vision, paresthesias, headache, fever, cough and bone pain. Rarely, CLS may occur. 

---